Gastrointestinal cancer drug shows promise4th April 2012
Bayer has said that its cancer drug has improved chances of survival in patients suffering from a type of gastrointestinal tumour and kept the condition from worsening, following a 199-patient late-stage trial.
Findings showed that a combination of Bayer’s tumour-fighting drug regorafenib and best supportive care prolonged survival in patients with metastatic gastrointestinal stromal tumours or GIST, when compared with a dummy drug and best supportive care. Bayer now plans to file for US approval for regorafenib to treat metastatic GIST.
Share this page
There are no comments for this article, be the first to comment!
Post your comment
Only registered users can comment. Fill in your e-mail address for quick registration.
Title: Gastrointestinal cancer drug shows promise
Author: Mark Nicholls
Article Id: 21585
Date Added: 4th Apr 2012